当前位置:首页 - 行情中心 - 易瑞生物(300942) - 财务分析 - 资产负债表

易瑞生物

(300942)

  

流通市值:22.52亿  总市值:22.52亿
流通股本:4.05亿   总股本:4.05亿

资产负债表

报告期2026-09-302026-06-302026-03-312025-12-31
公司类型通用通用通用通用
流动资产:
  货币资金477,513,157.1461,190,618412,014,778.36392,838,438.45
  交易性金融资产66,594,416.36122,970,949.26187,642,545.12235,295,655.31
  应收票据及应收账款125,239,668.5115,993,300.72102,742,507.13111,334,198
  其中:应收票据253,409634,910944,1871,123,897.96
        应收账款124,986,259.5115,358,390.72101,798,320.13110,210,300.04
  预付款项13,233,825.3712,985,532.0116,367,827.919,100,142.13
  其他应收款合计5,590,120.834,856,352.775,115,807.554,402,768.48
  存货75,833,055.7364,760,294.8562,276,117.1854,774,024.42
  其他流动资产11,089,458.5211,305,538.9312,095,642.1810,069,023.36
  流动资产合计775,093,702.41794,062,586.54798,255,225.43817,814,250.15
非流动资产:
  长期股权投资62,726,416.6863,990,573.0164,915,967.2378,520,051.4
  其他权益工具投资5,000,0005,017,377.435,000,0005,000,000
  固定资产558,596,742.95565,417,605.83569,785,559.5576,012,583.37
  在建工程4,785,063.863,017,476.882,261,746.782,261,746.78
  无形资产35,891,866.1336,378,399.0236,864,931.9137,351,464.8
  长期待摊费用294,332.42451,636.491,135,380.29541,072.59
  递延所得税资产14,315,785.311,854,701.189,743,309.327,046,695.5
  非流动资产合计681,610,207.34686,127,769.84689,706,895.03706,733,614.44
  资产总计1,456,703,909.751,480,190,356.381,487,962,120.461,524,547,864.59
流动负债:
  短期借款-11,000,00011,000,00021,000,000
  应付票据及应付账款38,807,513.0545,873,762.2244,768,316.4872,955,132.11
        应付账款38,807,513.0545,873,762.2244,768,316.4872,955,132.11
  预收款项290,454.34287,206.41413,841.868,606.34
  合同负债22,253,133.3720,987,483.2114,180,324.7717,182,705.33
  应付职工薪酬18,564,074.1918,260,638.4115,606,385.3121,589,845.65
  应交税费1,529,769.991,166,421.463,716,156.515,597,456.67
  其他应付款合计6,469,177.445,569,213.123,947,732.776,687,912.29
  一年内到期的非流动负债13,427,434.9514,416,598.2413,981,966.3913,551,694.17
  其他流动负债2,651,996.022,549,088.181,843,442.232,070,000.03
  流动负债合计103,993,553.35120,110,411.25109,458,166.26160,703,352.59
非流动负债:
  长期借款168,080,568.33171,297,841.72174,515,115.11155,966,607.22
  应付债券271,878,344.24266,933,326.62261,990,170.23257,029,652.59
  预计负债2,080,0002,080,0002,080,0002,080,000
  递延收益38,148,808.2939,322,386.640,496,794.8241,087,770.33
  非流动负债合计480,187,720.86479,633,554.94479,082,080.16456,164,030.14
  负债合计584,181,274.21599,743,966.19588,540,246.42616,867,382.73
所有者权益(或股东权益):
  实收资本(或股本)405,080,945405,077,895405,068,876405,068,764
  其他权益工具61,432,801.8361,437,856.0261,452,801.5261,452,987.54
  资本公积221,671,686.64221,643,752.22221,583,389.31221,564,679.31
  其他综合收益-901,036.76-339,906.43-113,455.01104,358.53
  盈余公积55,652,955.2555,652,955.2555,652,955.2555,652,955.25
  未分配利润122,853,289.13130,527,117.27149,976,995.45160,236,481.67
  归属于母公司股东权益合计865,790,641.09873,999,669.33893,621,562.52904,080,226.3
  少数股东权益6,731,994.456,446,720.865,800,311.523,600,255.56
  股东权益合计872,522,635.54880,446,390.19899,421,874.04907,680,481.86
  负债和股东权益合计1,456,703,909.751,480,190,356.381,487,962,120.461,524,547,864.59
公告日期2026-10-282026-08-282026-04-272026-04-27
审计意见(境内)标准无保留意见
TOP↑